Murae Organisor Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Murae Organisor şirketinin toplam hissedar öz sermayesi ₹558.7M ve toplam borcu ₹0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹1.2B ve ₹640.2M dir. Murae Organisor 'in FAVÖK'ü ₹1.2M faiz karşılama oranı 21.1 dur. Şirketin ₹117.1M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

₹0

Borç

Faiz karşılama oranı	21.1x
Nakit	₹117.14m
Eşitlik	₹558.67m
Toplam yükümlülükler	₹640.17m
Toplam varlıklar	₹1.20b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 542724 'nin kısa vadeli varlıkları ( ₹1.2B ) kısa vadeli yükümlülüklerini ( ₹640.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: 542724 un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 542724 borçsuzdur.

Borcun Azaltılması: 542724 şirketinin 5 yıl önce borç/öz sermaye oranı 60.6% iken borcu yok.

Borç Kapsamı: 542724 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 542724 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Murae Organisor Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Murae Organisor Limited has filed a Follow-on Equity Offering in the amount of INR 465 million.

New major risk - Shareholder dilution

Murae Organisor Limited to Report Q2, 2025 Results on Nov 14, 2024

Murae Organisor Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released

Murae Organisor Limited to Report Q1, 2025 Results on Aug 12, 2024

New major risk - Revenue and earnings growth

Murae Organisor Limited announced that it has received INR 247.499999 million in funding from IFL Enterprises Limited, Moneystar Tradelink Private Limited, Banke Tradelink Private Limited, Balmukund Tradelink Private Limited, Someshwara Tradelink Private Limited

Murae Organisor Limited to Report Q4, 2024 Results on May 30, 2024

High number of new and inexperienced directors

Murae Organisor Limited Announces Board Appointments

Murae Organisor Limited Appoints Sangita Rajpurohit as Company Secretary and Compliance Officer

Earum Pharmaceuticals Limited Approves Board Resignations

Third quarter 2024 earnings released: EPS: ₹0.001 (vs ₹0.22 in 3Q 2023)

Earum Pharmaceuticals Limited Announces Resignation of Sunil Kumar Patel as Chief Financial Officer

Earum Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Earum Pharmaceuticals Limited Approves Appointment of Vaghasiya Brijeshkumar Mathurbhai as Chief Financial Officer

Earum Pharmaceuticals Limited announced that it expects to receive funding from IFL Enterprises Limited, Moneystar Tradelink Private Limited, Banke Tradelink Private Limited, Balmukund Tradelink Private Limited, Someshwara Tradelink Private Limited and other investors

Earum Pharmaceuticals Limited announced that it expects to receive funding from IFL Enterprises Limited, Moneystar Tradelink Private Limited, Banke Tradelink Private Limited, Balmukund Tradelink Private Limited, Someshwara Tradelink Private Limited and other investors

Earum Pharmaceuticals Limited announced that it expects to receive funding from IFL Enterprises Limited, Moneystar Tradelink Private Limited, Banke Tradelink Private Limited, Balmukund Tradelink Private Limited, Someshwara Tradelink Private Limited and other investors

Earum Pharmaceuticals Limited Announces Resignation of Vijaykumar Patel as Managing Director

New minor risk - Share price stability

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Earum Pharmaceuticals Limited Approves Board Changes

New minor risk - Profit margin trend

First quarter 2024 earnings released

Earum Pharmaceuticals Limited, Annual General Meeting, Sep 16, 2023

Earum Pharmaceuticals Limited Announces Executive Changes

High number of new and inexperienced directors

Earum Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 14, 2023

Earum Pharmaceuticals Limited Announces Resignation of Madhuri Mistry from the Position of the Company Secretary

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

Full year 2023 earnings released: EPS: ₹0.33 (vs ₹0.36 in FY 2022)

Earum Pharmaceuticals Limited to Report Q4, 2023 Results on May 23, 2023

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released: EPS: ₹0.22 (vs ₹0.15 in 3Q 2022)

Earum Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 10, 2023

Earum Pharmaceuticals Limited Appoints Sumitkumar Patel as Independent Director, with Effect from 5Th November, 2022

Earum Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 05, 2022

Earum Pharmaceuticals Limited Appoints Madhuri Mistry as the Company Secretary and Compliance Officer

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Earum Pharmaceuticals Limited Announces Resignation of Bhumishth Patel as Managing Director

Earum Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released: EPS: ₹0.29 (vs ₹0.16 in 1Q 2022)

Earum Pharmaceuticals Limited to Report Q1, 2023 Results on Jul 14, 2022

Investor sentiment deteriorated over the past week

Earum Pharmaceuticals Limited Announces Resignation of Bhavesh N. Sonesara as Independent Director

Full year 2022 earnings released: EPS: ₹0.36 (vs ₹0.014 in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new and inexperienced directors

High number of new and inexperienced directors

Second quarter 2022 earnings released

Independent Director Hetarth Patel has left the company

Independent Director Hetarth Patel has left the company

Less than half of directors are independent

High number of new and inexperienced directors

Independent Director Bhavik Patel has left the company

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Non-Executive Director has left the company

New 90-day low: ₹79.00

Full year 2020 earnings released: EPS ₹58.82

Earum Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2020

New 90-day high: ₹87.50

Market pulls back on stock over the past week

New 90-day low: ₹66.00

New 90-day low - ₹66.50

Earum Pharmaceuticals Limited to Report Q4, 2020 Results on Jun 30, 2020